Credit: Roche

As on 15 February, the FDA likelihood of approval (LoA) for Roche’s (SIX:ROG) faricimab in neovascular age-related macular degeneration (wet AMD) went up 7 points, according to GlobalData’s LoA data. The update is due to Roche’s Phase III TENAYA trial (NCT03823287) reporting noninferior vision gains to a rival at double the dosing interval.

While faricimab previously had a 36% LoA, this increased to 43% after the results using GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. According to a 12 February media release, faricimab delivered noninferior visual improvement to Regeneron Pharmaceuticals’ (NASDAQ:REGN) Eylea (aflibercept). While Eylea is administered every two months, faricimab can be given in intervals up to four months, according to the same data release. Around half of people who qualified for extended dosing with faricimab could be treated every four months in the first year in the TENAYA and accompanying Phase III LUCERNE (NCT03823300) study for wet AMD, said the release. The studies evaluated faricimab administered at intervals of every two, three or four months, in contrast to Eylea given every two.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

On 17 December 2019, this news service reported that TENAYA and LUCERNE were powered for noninferiority versus Eylea. In addition, experts explained how Roche performed a 76-patient Phase II wet AMD trial called STAIRWAY (NCT03038880), which was powered to explore durability. It found that roughly 65% of patients could be extended to a treatment of once every four months. Roche has a market cap of USD 267.81bn (18 February).

Sean Rai-Roche is a Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.